

B³ sub C17
a component A comprising one or more compounds that are methyl or methylene donors,
a component B comprising one or more methyl transporters, and
a component C comprising one or more bioflavonoids.

2. (Amended) A composition according to claim 1, wherein component A comprises one or more compounds selected from the group consisting of betaine, dimethylglycine, sarcosine and serine, and their physiologically acceptable salts.

B⁴
3. (Twice Amended) A composition according to claim 1, wherein component B comprises one or more compounds selected from the group consisting of dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, and 5,10-methenyltetrahydrofolic acid, and their physiologically acceptable salts.

B⁵ sub C1
4. (Amended) A composition according to claim 3, wherein component B comprises L-5-methyltetrahydrofolic acid or a physiologically acceptable salt thereof.

B⁶
5. (Twice Amended) A composition according to claim 1, wherein component C comprises one or more compounds selected from the group consisting of mono-, di- and triglycoside bioflavonoids that contain an aglycone quercetin.

B⁷ sub C1
6. (Amended) A composition according to claim 5, wherein component C comprises one or more compounds selected from the group consisting of isoquercetin, quercetin, isoquercitrin, quercimeritrin, spiraeosid, rutin, and hyperin.

B⁸ sub C1
7. (Twice Amended) A method of treating or preventing a transmethylation disorder comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

8. (Twice Amended) A method of treating or preventing a cardiovascular disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

9. (Twice Amended) A method of treating or preventing an atherogenic and/or thrombogenic disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

10. (Twice Amended) A method of treating or preventing a disease associated with hyperhomocysteinemia comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

11. (Twice Amended) A method of treating or preventing premature occlusive arterial disease, severe vascular disease in infancy and childhood, progressive arterial stenosis, intermittent claudication, renovascular hypertension, ischemic cerebrovascular disease, premature retinal artery and retinal vein occlusion, cerebral occlusive arterial disease, occlusive peripheral arterial disease, premature death due to thromboembolic disease and/or ischemic heart disease, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

✓
Please cancel claim 12 without prejudice or disclaimer.

✓
Please add the following new claims:

12. A method of preparing a composition according to claim 1, comprising combining components A, B and C.

14. A composition according to claim 1 further comprising one or more nutritional substances, and/or one or more solid, liquid and/or semi liquid excipients or auxiliaries.

- Sub C17
15. A food or food supplement comprising a composition according to claim 1.
16. A pharmaceutical composition comprising a composition according to claim 1 and one or more pharmaceutically acceptable excipients or auxiliaries.
17. A pharmaceutical composition according to claim 16 that is lyophilized.
- B9
cont.
18. A composition according to claim 1, wherein the molar ratio of components A:B:C is 20,000:1:10,000 to 500:1:100.
19. A composition according to claim 1, wherein component A comprises one or more compounds selected from the group consisting of betaine, dimethylglycine, sarcosine and serine, and their physiologically acceptable salts, component B comprises one or more compounds selected from the group consisting of dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, and 5,10-methenyltetrahydrofolic acid, and their physiologically acceptable salts, and component C comprises one or more compounds selected from the group consisting of mono-, di- and triglycoside bioflavonoids that contain an aglycone quercetin.
20. A composition according to claim 5, wherein component C comprises one or more compounds selected from the group consisting of isoquercetin, quercetin, isoquercitrin, quercimeritrin, spiraeosid, rutin, and hyperin.
- Sub C17
21. A composition according to claim 1, wherein component B comprises one or more compounds selected from the group consisting of (6S)-tetrahydrofolic acid; 5-methyl-(6S)-tetrahydrofolic acid; 5-formyl-(6S)-tetrahydrofolic acid; 10-formyl-(6R)-tetrahydrofolic acid; 5,10-methylene-(6R)-tetrahydrofolic acid; 5,10-methenyl-(6R)-tetrahydrofolic acid; and

Sal
C17
their physiologically acceptable salts.

22. A composition according to claim 1, wherein component B comprises one or more compounds selected from the group consisting of derivatives of L- and S-glutamic acid.

23. A composition according to claim 1, wherein component B comprises 5-methyl-(6S)-tetrahydrofolic acid.

B⁹
cont.
24. A method of treating a transmethylation disorder comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

25. A method of treating a cardiovascular disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

26. A method of treating an atherogenic and/or thrombogenic disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

27. A method of treating a disease associated with hyperhomocysteinemia comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

28. A method of treating premature occlusive arterial disease, severe vascular disease in infancy and childhood, progressive arterial stenosis, intermittent claudication, renovascular hypertension, ischemic cerebrovascular disease, premature retinal artery and retinal vein occlusion, cerebral occlusive arterial disease, occlusive peripheral arterial disease, premature death due to thromboembolic disease and/or ischemic heart disease, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.--